Renalytix (NASDAQ:RNLX) trading rose 2.8%

Shares of Renalytix Plc (NASDAQ:RNLX – Get Your Free Report ) were up 2.8% during mid-day trading on Thursday. The stock traded as high as $0.39 and last traded at $0.37. 137,785 shares changed hands during mid-day trading, down 91% from the session’s average volume of 1,611,476 shares. Shares previously closed at $0.36.

Analysts set new price targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Renalytix in a research report on Friday, July 12th.

Check out our latest review of Renalytix

Renalytix stock performance

The company has a market cap of $30.78 million, a PE ratio of -0.95 and a beta of 2.77. The stock’s 50-day simple moving average is $0.36 and its 200-day simple moving average is $0.60.

Renalytix (NASDAQ:RNLX – Get Your Free Report ) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.08) earnings per share for the quarter. Renalytix had a negative net margin of 1,687.80% and a negative return on equity of 1,008.88%. The firm had revenue of $0.54 million during the quarter. On average, sell-side analysts forecast that Renalytix Plc will post -0.3 EPS for the current fiscal year.

Institutional inputs and outputs

An institutional investor recently bought a new position in shares of Renalytix. Levin Capital Strategies LP purchased a new position in shares of Renalytix Plc (NASDAQ:RNLX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies LP owned 0.72% of Renalytix at the end of the most recent quarter. Institutional investors and hedge funds own 9.92% of the company’s shares.

Renalytix Company Profile

(Get a free report)

Renalytix Plc develops artificial intelligence in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that uses an AI-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique score of risk to the patient.

Recommended articles

Get news and reviews for Renalytix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Renalytix and related companies with MarketBeat.com’s FREE daily email newsletter.